Sugi Predict

Sugi Predict / Compounds / SCHEMBL1051087

SCHEMBL1051087

SCHEMBL1051087

Cc1cc(C)nc(S(C)(=O)=O)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.52
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ ALDH1A1 P00352 6/20 0.42
▸ KDM4E B2RXH2 4/20 0.42
▸ GAA P10253 3/20 0.42
▸ MAPT P10636 2/20 0.42
▸ KMT2A Q03164 5/20 0.41
▸ MEN1 O00255 3/20 0.41
▸ CYP3A4 P08684 2/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ POLB P06746 2/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40
▸ SDHB P21912 4/20 0.40
▸ TSHR P16473 1/20 0.38
▸ BPTF Q12830 1/20 0.38
▸ HPGD P15428 3/20 0.37
▸ STAT3 P40763 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7754155 0.86 LMNA (0.45) LMNASMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL10519534 0.84 NOS3 (0.50) LMNASMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL6296316 0.84 LMNA (0.44) LMNASMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL10452895 0.81 BPTF (0.57) LMNASMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL6561352 0.81 SMN1; SMN2 (0.78) LMNASMN1; SMN2ALDH1A1KDM4EKMT2A
SCHEMBL76774 0.80 SDHB (0.60) LMNASMN1; SMN2ALDH1A1KDM4EMAPT
SCHEMBL9762452 0.78 LMNA (0.39) LMNASMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL8820190 0.78 TLR8 (0.54) LMNASMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL9795874 0.78 NOS2 (0.41) LMNASMN1; SMN2ALDH1A1KDM4EGAA
SCHEMBL9795870 0.78 NOS2 (0.41) LMNASMN1; SMN2ALDH1A1KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 172 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114933568-B Preparation method of 4, 6-dimethyl-2-methylsulfonyl pyrimidine 抚州润泰药业有限公司 2024-11-26 — — CN claimed
CN-118122242-A Semiconductor heterogeneous photoelectrocatalysis flow reactor and application thereof 浙江大学 2024-06-04 — — CN claimed
CN-114933568-A Preparation method of 4, 6-dimethyl-2-methylsulfonyl pyrimidine 抚州润泰药业有限公司 2022-08-23 — — CN claimed
CN-108250151-B Preparation method of ambrisentan 济南周行医药科技有限公司 2021-03-16 — — CN claimed
CN-108250151-A A kind of preparation method of ambrisentan 济南周行医药科技有限公司 2018-07-06 — — CN claimed
US-9533960-B2 Preparation process of carboxylic acid derivatives and intermediates thereof KERN PHARMA, S.L. (ES) 2017-01-03 — — US claimed
CN-106011194-A Preparation method of ambrisentan 西安大唐制药集团有限公司 2016-10-12 — — CN claimed
CN-103739557-B A kind of synthetic method of 4,6-dimethyl-2-methanesulfonyl pyrimidine YELLOW RIVER DELTA JINGBO CHEMICAL RESEARCH INSTITUTE CO., LTD. (CN) 2015-10-21 — — CN claimed
CN-103420811-B Intermediate compound used for preparing Ambrisentan, preparation method thereof, and preparation of Ambrisentan SHANGHAI INST PHARM INDUSTRY 2015-04-15 — — CN claimed
US-8962832-B2 Process for the preparation of ambrisentan and novel intermediates thereof CADILA HEALTHCARE LIMITED (IN) 2015-02-24 — — US claimed
US-20130060031-A1 PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN NATCO PHARMA LIMITED (IN) 2013-03-07 — — US claimed
EP-2547663-A1 A PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN Natco Pharma Limited (IN) 2013-01-23 — — EP claimed
US-20120184573-A1 PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2012-07-19 — — US claimed
EP-2451786-A2 IMPROVED PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF Cadila Healthcare Limited (IN) 2012-05-16 — — EP claimed
US-20110263854-A1 Improved Process For The Preparation Of Endothelin Receptor Antagonists MSN LABORATORIES LIMITED (IN) 2011-10-27 — — US claimed
WO-2011114338-A1 A PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN NATCO PHARMA LIMITED (IN) 2011-09-22 — — WO claimed
EP-2350024-A2 IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS MSN Laboratories Limited (IN) 2011-08-03 — — EP claimed
WO-2011004402-A2 IMPROVED PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF CADILA HEALTHCARE LIMITED (IN) 2011-01-13 — — WO claimed
WO-2010091877-A2 PROCESS FOR PRODUCING AMBRISENTAN RATIOPHARM GMBH (DE) 2010-08-19 — — WO claimed
WO-2010070658-A2 IMPROVED PROCESS FOR THE PREPARATION OF ENDOTHELIN RECEPTOR ANTAGONISTS MSN LABORATORIES LIMITED (IN) 2010-06-24 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130060031-A1 PROCESS FOR THE PREPARATION OF HIGHLY PURE AMBRISENTAN AGTR2, PDE7A, ACVR1B LMNA 1584/4885SMN1; SMN2 3479/4885ALDH1A1 2101/4885
US-20110263854-A1 Improved Process For The Preparation Of Endothelin Receptor Antagonists EDNRA, EDNRB, ECE1 LMNA 1886/4885SMN1; SMN2 4390/4885ALDH1A1 4222/4885
US-20120184573-A1 PROCESS FOR THE PREPARATION OF AMBRISENTAN AND NOVEL INTERMEDIATES THEREOF ACVR1, ACVR1B, CYP11B1 LMNA 1296/4885SMN1; SMN2 4614/4885ALDH1A1 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.